News

The OptimHal-ProtecSom Laboratory exposes its work during DDL 2019 (Drug Delivery To The Lungs)

 

The Aerosol Society organized its 30th DDL congress in Edinburgh from December 11 to 13.

It is a must-attend annual forum for scientists, academics, clinicians, regulatory and industry experts involved in the development of inhalation medication. On the program, five thematic sessions each with a combination of conferences by experts in the field of inhalation and by students working to advance respiratory science.

 

During this congress, Thierry Porée, scientific director of the OptimHal-ProtecSom Laboratory, presented at a conference our latest work on the inhalation chamber for CombiHaler® mechanical ventilation circuits. An innovation !

 

 

CombiHaler® is an inhalation chamber for mechanical ventilation. It enables the simultaneous administration of medication by a metered dose inhaler and a vibrating mesh nebulizer.

It is intended to be used in hospitals, intensive care, or home hospitalization.

 

 

Research and results of interest have been presented by the OptimHal-ProtecSom laboratory.

Heating and humidifying a mechanical ventilation circuit is needed to protect the lungs of patients under invasive respiratory assistance. However, heat and humidity reduce the dose of aerosols delivered to the patient. We assessed the impact of heat and humidity on in vitro drugs delivery using pressurized metered dose inhaler and vibrating mesh nebulizer with CombiHaler®

This work has demonstrated the advantage of using an inhalation chamber both with a vibrating mesh nebulizer and with a metered dose inhaler, in comparison with the usually used T-pieces.

It also demonstrated that switching off the heated humidifier located in a mechanical ventilation circuit during drug administration did not increase the delivered dose and that the position of the inhalation chamber in the heated and humidified mechanical ventilation circuit had an important influence on this delivered dose.

 

 

Découvrir l’étude

ERS: European Respiratory Medicine Event

The European Respiratory Society (ERS), organized its 29th congress from 28 September to 02 October 2019 in Madrid, Spain. Showcasing the excellence of respiratory medicine, it is an essential event for all pneumology professionals and the patient associations concerned. It brings together more than 15,000 doctors, scientists and other specialists in respiratory medicine (research laboratories, etc.).

 

This event promotes scientific research and provides access to educational resources on diseases such as asthma, the heart of the Optimhal-Protecsom laboratory.

.

 

 

Promising resultats presented by OptimHal-ProtecSom

 

The Optimhal-Protecsom laboratory actively participated in this knowledge sharing by presenting its latest research on several inhalation chambers for mechanical ventilation circuits, including Combihaler.

 

Combihaler® is an inhalation chamber for mechanical ventilation systems. It allows for the simultaneous administration of metered-dose drugs and a mesh nebulizer.

In this study, the in vitro performances of several spacers, including CombiHaler®, were evaluated for drug delivery with pressurized metered dose inhaler (pMDI) and vibrating mesh nebulizer, in comparison with T adapters usually used, in an adult mechanical ventilation model.

 

Results showed that in vitro drug delivery is higher when using a spacer instead of T pieces, with both a pMDI and a vibrating mesh nebulizer.

 

CombiHaler has similar or higher in vitro performances than other spacers and permits the use of both a pMDI and a vibrating mesh nebulizer without dismantling the breathing circuit : these are new successful results which strengthen our goals and our purpose of continuous improvement. 

 

Each year, the Optimhal-Protecsom laboratory invests more than 25% of its turnover in research. This is an essential point for designing tomorrow’s medical devices with a constant goal : to improve the quality of life of patients and facilitate the work of caregivers.

 

Discover the study


             

Coughing, runny nose, stinging, itching, it’s red… What if it was an allergy to mites? It’s the high season!

In autumn, all the conditions are met to promote the proliferation of dust mites: heated housing, less airy, closed windows and reduced light are all factors that contribute to the concentration of allergenic particles in your indoor environment.

 

More than 3 in 10 French people suffer from allergy to dust mites and many people ignore it or minimize its consequences.

 

 

So, are you one of those allergic people who ignore themselves ? 

Among the 35% of French people who say they are allergic, 1 in 2 people considers that it is not a “real” disease and is thus exposed to a sometimes very serious evolution of their allergic disease. Asthma has an allergic origin for 80% of children and 50% of adults.

Respiratory illness is not to be taken lightly!


The association Asthme & Allergies calls, through an information and awareness campaign, patients and parents of allergic children to mobilize to better and faster detect allergy to dust mites in order to avoid these evolutions to asthma or other severe pathologies.

 

The Protecsom Laboratory, a specialist in allergen protection and improvement of the quality of life of patients, actively participates in this new awareness campaign of the association Asthma & Allergies, with several other partners and actors in the fight against mite allergy.

 

Visit the website

 

A 100% digital campaign !

 

This awareness campaign is deployed in the media and on social networks.
Discover four videos that feature the different symptoms of mite allergy (Eternity, Difficult Awakening, Runny Nose, etc.) and a page to answer all questions related to mite allergy. (Symptoms, Solutions and Risks).
A game created by the association Asthma & Allergy may also allow you to gain your protection. Be vigilant !